Synthetic and recombinant antithrombin drugs

Bibliography

• FENTON JW II: Thrombin functions and antithrom- botic intervention. Thromb. Haemost. (1995) 74(1)493–498.
   Google Scholar
• STUBBS MT, BODE W: A player of many parts: the spot-light falls on thrombin's structure. Thromb. Res. (1993) 69 (0 :1–58.
   PubMedGoogle Scholar
• CASTELLINO FJ: Human protein C and activated protein C. Components of the human anticoagulation system. Trends Cardiovasc. Med. (1995) 5(2):55–62.
   PubMed Web of Science ®Google Scholar
• ESMON CT, SCHWARZ HP: An update on clinical and ba-sic aspects of the protein C anticoagulant pathway. Trends Cardiovasc. Med. (1995) 5(4):141–148.
   PubMed Web of Science ®Google Scholar
• PEARSON JD: Endothelial cell function and thrombo-sis. Baillieres Clin. Haematol (1994) 7(3):441–452.
   PubMedGoogle Scholar
• WU KK, THIAGARAJAN P: Role of endothelium in thrombosis and hemostasis. Ann. Rev. Med. (1996) 47:315–331.
   PubMed Web of Science ®Google Scholar
• COLLEN D, LUNEN HR, TODD PA, GOA KL: Tissue-type plasminogen activator: a review of its pharmacology and therapeutic use as a thrombolytic agent. Drugs (1989) 38(3):346–388.
   PubMed Web of Science ®Google Scholar
• DICHEK D, QUERTERMOUS T: Thrombin regulation of mRNA levels of tissue plasminogen activator inhibitor-1 in cultured human umbilical vein endothe-lial cells. Blood (1989) 74(1):222–228.
   PubMed Web of Science ®Google Scholar
• KANTHOU C, BENZAKOUR 0: Cellular effects of throm-bin and their signalling pathways. Cell Pharmacol (1995) 2:293–302.
   Google Scholar
• DE CATERINA R, SICARI R: Cellular effects of thrombin:pharmacology of the receptor(s) in various cell types and possible development of receptor antagonists. Pharmacol. Res. (1993) 27(0:1–19.
   PubMedGoogle Scholar
• VU TKH, HUNG DT, WHEATON VI, COUGHLIN SR: Mo-lecular cloning of a functional thrombin receptor re-veals a novel proteolytic mechanism of receptor activation. Cell (1991) 64 (6):1057–1068.
   PubMed Web of Science ®Google Scholar
• COUGHLIN SR: Thrombin receptor structure and func-tion. Thromb. Haemost. (1993) 70(0:184–187.
   PubMedGoogle Scholar
• BRASS LF, MOLINO M: Protease-activated G-protein-coupled receptors on human platelets and endothelial cells. Thromb. Haemost. (1997) 78 (1) :234–241.
   PubMed Web of Science ®Google Scholar
• MOLINO M, WOOLKALIS MJ, REAVEY-CANTWELL J et al.: Endothelial cell thrombin receptors and PAR-2. two protease-activated receptors located in a single cellu-lar environment. J. Biol. Chem. (1997) 272(17):11133–11141.
   Google Scholar
• BRASS LF: Issues in the development of thrombin re-ceptor antagonists. Thromb. Haemost. (1995) 74(1):499–505.
   PubMed Web of Science ®Google Scholar
• BERNATOWICZ MS, KLIMAS CE, HARTL K eta]. : Develop-ment of potent thrombin receptor antagonist pep-tides. J. Med. Chem. (1996) 39(25):4879–4887.
   Google Scholar
• SEILER SM: Thrombin receptor antagonists. Semin. Thromb. Hemost. (1996) 22(3):223–232.
   PubMed Web of Science ®Google Scholar
• BRASS LF: Thrombin receptor antagonists: a work in progress. Coron. Artery Dis. (1997) 1:49–58.
   Google Scholar
• ROSENBERG RD, ROSENBERG JS: Natural anticoagulant mechanisms. J. Clin. Invest. (1984) 74(1):1–6.
   PubMed Web of Science ®Google Scholar
• TOLLEFSEN DM: In sight into the mechanism of action of heparin co-factor II. Thromb. Haemost. (1995) 74(5):1209–1214.
   PubMed Web of Science ®Google Scholar
• DAHLBACK B: The protein C anticoagulant system: in-herited defects as basis for venous thrombosis. Thromb. Res. (1995) 77(0:1–43.
   PubMed Web of Science ®Google Scholar
• BROZE GJ JR: Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coag. Fibri-not. (1995) 6 (Suppl. 1):S7–S13.
   Google Scholar
• FENTON JW II: Thrombin bioregulatory functions. Adv. Clin. Enzymol (1988) 6:186–193.
   Google Scholar
• TALBOT MD, BUTLER KD: Potential clinical uses of thrombin inhibitors. Drug News Perspect. (1990) 3(6):357–363.
   Google Scholar
• IYER L, FAREED J: Recombinant hirudin: a perspective. Exp. Opin. Invest. Drugs (1996) 5(5):469–494.
   Google Scholar
• MARKWARDT F: The development of hirudin as an anti-thrombotic drug. Thromb. Res. (1994) 74 (1) :1–23.
   PubMed Web of Science ®Google Scholar
• CALLAS D, FAREED J: Comparative pharmacology of site directed antithrombin agents. Implication in drug development. Thromb. Haemost. (1995) 74(1) :473–481.
   PubMed Web of Science ®Google Scholar
• ESSLINGER HU, HAAS S, MAURER R et al.: Pharmacody-namic and safety results of PEG-hirudin in healthy vol-unteers. Thromb. Haemost. (1997) 77(5):911–919.
   PubMed Web of Science ®Google Scholar
• NOESKE-JUNGBLUT C, HAENDLER B, DONNER P et al.:Triabin: a highly potent exosite inhibitor of thrombin. J. Biol. Chem. (1995) 270(48):28629–28634.
   PubMed Web of Science ®Google Scholar
• GLUSA E, BRETSCHNEIDER E, DAUM J, NOESKE-JUNGBLUT C: Inhibition of thrombin-mediated cellular effects by triabin, a highly potent anion-binding exo-site thrombin inhibitor. Thromb. Haemost. (1997) 77(6):1196–1200.
   PubMed Web of Science ®Google Scholar
• MARAGANORE JM, BOURDON P, JABLONSKI J, RA-MACHANDRAN KL, FENTON JW, II: Design and charac-terization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry (1990) 29(30):7095–7101.
   PubMedGoogle Scholar
• MARAGANORE JM: Direct thrombin inhibitors: Hiru-log. In: New Therapeutic Agents in Thrombosis and Throm-bolysis. Sasahara AA, Loscalzo J (Eds.) Marcel Dekker, Inc., New York, Basel, Hongkong (1997) :191–208.
   Google Scholar
• FENTON JAN II, NI F, WITTING JI, BREZNIAK DV, ANDER- SEN TT, MALIK AB: The rational design of thrombin-directed antithrombotics. In: The Design of Synthetic In-hibitors of Thrombin. Claeson G (Ed.), Plenum Press, New York (1993):1–13
   Google Scholar
• HAUPTMANN J, MARKWARDT F: Pharmacological as-pects of the development of selective synthetic throm-bin inhibitors as anticoagulants. Semin. Thromb. Hemost. (1992) 18(2):200–217.
   PubMed Web of Science ®Google Scholar
• MARKWARDT F, STÜRZEBECHER J: Inhibitors of trypsin and trypsin-like enzymes with a physiological role. In: Design of enzyme inhibitors as drugs. Sandler M, Smith HJ (Eds.), Oxford University Press, Oxford, (1989):619–649.
   Google Scholar
• SHAFER JA: Direct thrombin inhibitors: active-site in-hibitors of thrombin. In: New Therapeutic Agents in Thrombosis and Thrombolysis. Sasahara AA, Loscalzo J (Eds.) Marcel Dekker, Inc., New York, Basel, Hongkong (1997) :143–157.
   Google Scholar
• POWERS JC, KAM CM: Synthetic substrates and inhibi-tors of thrombin. In: Thrombin: Structure and Function. Berliner LJ (Ed.), Plenum Press, New York; (1992):117–158.
   Google Scholar
• TAPPARELLI C, METTERNICH R, EHRHARDT C, COOK NS:Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. Trends Pharmacol. Sci. (1993) 14(10366–376.
   Google Scholar
• STONE SR, TAPPARELLI C: Thrombin inhibitors as anti-thrombotic agents: the importance of rapid inhibi-tion. J. Enzyme Inhib. (1995) 9(0:3–15.
   PubMedGoogle Scholar
• DAS J, KIMBALL SD: Thrombin active site inhibitors.Bioorgan. Med. Chem. (1995) 3(8):999–1007.
   Google Scholar
• WILEY MR, FISHER MJ: Small-molecule direct thrombininhibitors. Exp. Opin. Ther. Patents (1997) 7(11):1265–1282.
   Web of Science ®Google Scholar
• BOCK LC, GRIFFIN LC, LATHAM JA, VERMAAS EH, TOOLEJJ: Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature (1992) 355(6360)564–566.
   Google Scholar
• PABORSKY LR, MCCURDY SN, GRIFFIN LC, TOOLE JJ, LE-UNG UK: The single-stranded DNA aptamer-binding site of human thrombin. J. Biol. Chem. (1993) 268(28):20808–20811.
   PubMed Web of Science ®Google Scholar
• GRIFFIN LC, TIDMARSH GF, BOCK LC, TOOLE JJ, LEUNGUK: In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstra-tion of regional anticoagulation in extracorporeal cir-cuits. Blood (1993) 81(12):3271–3276.
   PubMed Web of Science ®Google Scholar
• BUSH LR: Argatroban, a selective, potent thrombin in-hibitor. Cardiovasc. Drug Rev. (1991) 9 (3):247–263.
   Google Scholar
• KAISER B, HAUPTMANN J: Pharmacology of syntheticthrombin inhibitors of the tripeptide type. Cardiovasc. Drug Rev. (1992) 10(1):71–87.
   Google Scholar
• WALSMANN P, KAISER B: Biochemical and pharmacol-ogical properties of recombinant hirudin. Drugs Today (1989) 25(7):473–485.
   Google Scholar
• KAISER B: Anticoagulant and antithrombotic actions of recombinant hirudin. Semin. Thromb. Hemost. (1991) 17(2):130–136.
   PubMed Web of Science ®Google Scholar
• CALLAS D, FAREED J: Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method. Thromb. Res. (1996) 83 (6):463–468.
   PubMed Web of Science ®Google Scholar
• POTZSCH B, MADLENER K, SEELIG C, RIESS CF, GREIN- ACHER A, MeLLER-BERGHAUS G: Monitoring of r-hirudin anticoagulation during cardiopulmonary by-pass - assessment of the whole blood ecarin clotting time. Thromb. Haemost. (1997) 77(5):920–925.
   PubMed Web of Science ®Google Scholar
• KAISER B, KOZA M, WALENGA JM, FAREED J: Flow cy- tometric evaluation of the effect of various thrombin inhibitors on platelet activation in whole blood. Thromb. Res. (1996) 82(3):257–263.
   PubMed Web of Science ®Google Scholar
• GLUSA E: Hirudin and platelets. Semin. Thromb. Hemost.(1991) 17(2):122–125.
   PubMed Web of Science ®Google Scholar
• GLUSA E: Platelet aggregation in recombinant hirudin- antico agulate d blood. Haemostasis (1991) 21 (Suppl. 0:116–120.
   Google Scholar
• KIRCHMEIER CM, BELLINGER OK, SCHULZ B, BREDDIN HK: Effect of recombinant hirudin on cytosolic Ca2+ concentration using different platelet stimulators. Haemostasis (1991) 21 (Suppl 0:121–126.
   PubMedGoogle Scholar
• BERRY CN, GIRARD D, GIRARDOT C et al.: Antithrom- botic activity of argatroban in experimental thrombo-sis in the rabbit. Semin. Thromb. Hemost. (1996) 22 (3) :233–241.
   PubMed Web of Science ®Google Scholar
• KELLY A, MARAGANORE JM, BOURDON P, HARKER LA: Antithrombotic effects of synthetic peptides targeting different functional domains of thrombin. Proc. Natl. Acad. Sci. USA (1992) 89(13):6040–6044.
   PubMed Web of Science ®Google Scholar
• BERRY CN, GIRARD D, LOCHOT S, LECOFFRE C: Anti- thrombotic actions of argatroban in rat models of ve-nous, 'mixed' and arterial thrombosis, and its effect on the trail transection bleeding time. Br. J. Pharmacol (1994) 113(4):1209–1214.
   PubMed Web of Science ®Google Scholar
• MARKWARDT F, KAISER B, NOWAK G: Studies on anti-thrombotic effects of recombinant hirudin. Thromb. Res. (1989) 54(5):377–388.
   PubMed Web of Science ®Google Scholar
• KAISER B, MARKWARDT F: Experimental studies on the antithrombotic action of a highly effective, synthetic thrombin inhibitor. Thromb. Haemost. (1986) 55 (2):194–196.
   PubMed Web of Science ®Google Scholar
• HOFFMANN A, MARKWARDT F: Inhibition of thethrombin-platelet reaction by hirudin. Haemostasis (1984) 14(2):164–169.
   PubMedGoogle Scholar
• BENZAKOUR 0, KANTHOU C: Cellular and molecularevents in atherogenesis: basis for pharmacological and gene therapy approaches to restenosis. Cell. Phar-macol (1996) 3:7–22.
   Google Scholar
• SCHWARTZ RS, HOLMES JR DR, TOPOL EJ: The restenosisparadigm revisited: an alternative proposal for cellu-lar mechanisms. J. Am. Coll. Cardiol (1992) 20 (5):1284–1293. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(6)
   Google Scholar
• MCNAMARA CA, SAREMBOCK IJ, BACHHUBER BG et al: Thrombin and vascular smooth muscle cell prolifera-tion: implications for atherosclerosis and restenosis. Semin. Thromb. Hemost. (1996) 22(2):139–144.
   PubMed Web of Science ®Google Scholar
• ALT MN, VILLARREAL-LEVY G, SCHAFER AT: The role of thrombin and thrombin inhibitors in coronary angio-plasty. Chest (1995) 108(5):1409–1419.
   PubMed Web of Science ®Google Scholar
• SAREMBOCK IJ, GERTZ SD, GIMPLE LW et al.: Effective-ness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation (1991) 84 (1) :232–243.
   PubMed Web of Science ®Google Scholar
• HERAS M, CHESEBRO JH, WEBSTER MWI et al.: Hirudin,heparin, and placebo during deep arterial injury in the pig: the in vivo role of thrombin in platelet-mediated thrombosis. Circulation (1990) 82(4)1476–1484.
   Google Scholar
• KAISER B, SIMON A, MARKWARDT F: Antithrombotic ef-fects of recombinant hirudin in experimental angio-plasty and intravascular thrombolysis. Thromb. HaemosL (1990) 63(1):44–47.
   PubMed Web of Science ®Google Scholar
• IMANISHI T, ARITA M, HAMADA M, TOMOBUCHI Y, HANO T, NISHIO I: Effects of locally administration of argatroban using a hydrogel-coated balloon catheter on intimal thickening induced by balloon injury. Ja-pan. Circ. J. (1997) 61(3):256–262.
   PubMed Web of Science ®Google Scholar
• ABENDSCHEIN DR, RECCHIA D, MENG YY et al: Inhibi-tion of thrombin attenuates stenosis after arterial in-jury in minipigs. J. Am. Coll. Cardiol. (1996) 28 (7):1849–1855.
   PubMed Web of Science ®Google Scholar
• UNTERBERG C, SANDROCK D, NEBENDAHL K, BUCHWALD AB: Reduced acute thrombus formation results in decreased neointimal proliferation after coronary angioplasty. J. Am. Coll. Cardiol. (1995) 26 (7): 1747–1754.
   PubMed Web of Science ®Google Scholar
• BARRY WL, WIEGMAN PJ, GIMPLE LW et al.: A new single-injury model of balloon angioplasty in cholesterol-fed rabbits: beneficial effect of hirudin and comparison with double-injury model. Lab. Invest. (1997) 77(1):109–116.
   PubMed Web of Science ®Google Scholar
• MULLER DW, GORDON D, TOPOL EJ, LEVY RJ, GOLOMBG: Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting. Am. Heart J. (1996) 131(2):211–218.
   PubMed Web of Science ®Google Scholar
• HADOKE PW, WADSWORTH RM, WAINWRIGHT CL, BUT-LER KD, GIDDINGS MJ: Subcutaneous infusion of r-hirudin does not inhibit neointimal proliferation after angioplasty of the subclavian artery in cholesterol-fed rabbits. Coron. Artery Dis. (1996) 7(8)599–608.
   Google Scholar
• GOLD HK, TORRES FW, GARABEDIAN HD et al: Evidencefor a rebound coagulation phenomenon after cessa-tion of a 4-hour infusion of a specific thrombin inhibi-tor in patients with unstable angina pectoris. J. Am. Coll Cardiol (1993) 21(5):1039–1047.
   PubMed Web of Science ®Google Scholar
• ZOLDHELYI P, BICHLER J, OWEN WG et al.: Persistentthrombin generation in humans during specific thrombin inhibition with hirudin. Circulation (1994) 90 (6):2671–2678.
   PubMed Web of Science ®Google Scholar
• GINSBERG JS, NURMOHAMED MT, GENT M et al.: Effects on thrombin generation of single injections of hini- TM login patients with calf vein thrombosis. Thromb. Haemost. (1994) 72(4):523–525.
   PubMed Web of Science ®Google Scholar
• BITTL JA, STRONY J, BRINKER JA et al. for the Hirulog An-gioplasty Study Investigators: Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. New Engl. J. Med. (1995) 333(12):764–769.
   PubMed Web of Science ®Google Scholar
• KO FN, YANG YC, HUANG SC, OU JT: Coagulation factor Xa stimulates platelet-derived growth factor release and mitogenesis in cultured vascular smooth muscle cells of rat. J. Clin. Invest. (1996) 98(6):1493–1501.
   PubMed Web of Science ®Google Scholar
• GASIC GP, ARENAS CP, GASIC TB, GASIC GJ: Coagulation factors X, Xa, and protein S as potent mitogens of cul-tured aortic smooth muscle cells. Proc. Natl. Acad. ScL USA (1992) 89(6):2317–2320.
   PubMed Web of Science ®Google Scholar
• RAGOSTA M, GIMPLE LW, GERTZ D et al.: Specific factor Xa inhibition reduces restenosis after balloon angio-plasty of atherosclerotic femoral arteries in rabbits. Circulation (1994) 89 (3) :1262–1271.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ RS, HOLDER DJ, HOLMES JR DR et al.: Neoin-timal thickening after severe coronary artery injury is limited by short-term administration of a factor Xa in-hibitor. Results in a porcine model. Circulation (1996) 93 (8): 1542–1548.
   Google Scholar
• GLUSA E: Vascular effects of thrombin. Semin. Thromb. Hemost. (1992) 18(3):296–304.
   PubMed Web of Science ®Google Scholar
• WINN MJ, JAIN K, KU DD: Argatroban and inhibition of the vasomotor actions of thrombin. J. Cardiovasc. Phar-macol (1993) 22(5):754–760.
   PubMed Web of Science ®Google Scholar
• KAPLANSKI G, FABRIGOULE M, BOULAY V et al. Throm- bin induces endothelial type II activation in vitro: IL-1 and TNF-alpha-independent IL-8 secretion and E-selectin expression. J. Immunol (1997) 158(11) 5435–5414
   PubMed Web of Science ®Google Scholar
• RONDEAU E, HE CJ, ZACHARIAS U, SRAER JD: Thrombin stimulation of renal cells. Semin. Thromb. Hemost. (1996) 22(2):135–138.
   PubMed Web of Science ®Google Scholar
• SUIDAN HS, NICLOU SP, MONARD D: The thrombin re-ceptor in the nervous system. Semin. Thromb. Hemost. (1996) 22(2):125–133.
   PubMed Web of Science ®Google Scholar
• PANETTIERI RA JR, HALL IP, MAKI CS, MURRAY RK: Alpha-thrombin increases cytosolic calcium and in-duces human airway smooth muscle cell prolifera-tion. Am. J. Respir. Cell Mol. Biol. (1995) 13(2):205–216.
   PubMed Web of Science ®Google Scholar
• KAISER B, FAREED J, HOPPENSTEADT D et al: Influence of recombinant hirudin and unfractionated heparin on thrombin and factor Xa generation in extrinsic and intrinsic activated systems. Thromb. Res. (1992) 65 (2) :157–164.
   PubMed Web of Science ®Google Scholar
• KAISER B, CALLAS D, HOPPENSTEADT D, MALLINOWSKAK, FAREED J: Comparative studies on the inhibitory spectrum of recombinant hirudin, DuP 714 and hepa-rin on thrombin and factor Xa generation in bio-chemically defined systems. Thromb. Res. (1994) 73 (5):327–335.
   PubMed Web of Science ®Google Scholar
• OFOSU FA, FENTON II JW, MARAGANORE J et al: Inhibi- tion of the amplification reactions of blood coagula-tion by site-specific inhibitors of a-thrombin. Biochem. J. (1992) 283 (Pt 3):893–897.
   PubMedGoogle Scholar
• GALLISTL S, MUNTEAN W: Thrombin-hirudin complex formation, thrombin-antithrombin III complex for-mation, and thrombin generation after intrinsic acti-vation of plasma. Thromb. Haemost. (1994) 72(3)387–392.
   Google Scholar
• GALLISTL S, MUNTEAN W, LEIS HJ: Effects of heparin and hirudin on thrombin generation and platelet ag-gregation after intrinsic activation of platelet rich plasma. Thromb. Haemost (1995) 74 (4) :1163–1168.
   PubMed Web of Science ®Google Scholar
• KAISER B, FAREED J, WALENGA JM, HOPPENSTEADT D,MARKWARDT F: In vitro studies on thrombin genera-tion in citrated, r-hirudinized and heparinized whole blood. Thromb. Res. (1991) 64 (5) :589–596.
   PubMed Web of Science ®Google Scholar
• WEITZ JI: Activation of blood coagulation by plaquerupture: mechanisms and prevention. Am. J. Cardiol (1995) 75(6):18B-22B.
   Google Scholar
• GAST A, TSCHOPP TB, SCHMID G, HILPERT K, ACKER-MANN J: Inhibition of clot-bound and free (fluid-phase) thrombin by a novel synthetic thrombin in-hibitor (Ro 46-6240), recombinant hirudin and hepa-rin in human plasma. Blood Coag. Fibrinol. (1994) 5 (6):879–887.
   PubMed Web of Science ®Google Scholar
• BEIMOND BJ, FRIEDERICH PW, LEVI M et al.: Compari-son of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. Circulation (1996) 93(1):153–160.
   PubMed Web of Science ®Google Scholar
• ARNLJOTS B, BERGQVIST D: Inhibition of heparin-resistant microarterial thrombosis by recombinant hi-rudin: a specific thrombin inhibitor. Plast. Reconstr. Surg. (1995) 95(5):894–900.
   PubMed Web of Science ®Google Scholar
• BERRY CN, GIRARDOT C, LECOFFRE C, LUNVEN C: Ef-fects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb. Hae-most. (1994) 72(3):381–386.
   PubMed Web of Science ®Google Scholar
• PRAGER NA, ABENDSCHEIN DR, MCKENZIE CR, EISEN-BERG PR: Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circula-tion (1995) 92(4):962–967.
   PubMed Web of Science ®Google Scholar
• EISENBERG PR, SIEGEL JE, ABENDSCHEIN DR, MILETICH JP: Importance of factor Xa in determining the proco-agulant activity of whole-blood clots. J. Clin. Invest. (1993) 91(5):1877–1883.
   PubMed Web of Science ®Google Scholar
• THE GLOBAL USE OF STRATEGIES TO OPEN OCCLUDED CORONARY ARTERIES (GUSTO) IIA INVESTIGATORS: Randomized trial of iv. heparin versus recombinant hirudin for acute coronary syndromes. Circulation (1994) 90(4):1631–1637.
   Google Scholar
• THE GLOBAL USE OF STRATEGIES TO OPEN OCCLUDED CORONARY ARTERIES (GUSTO) IIB INVESTIGATORS: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. New. Engl. J. Med. (1996) 335 (10:775–782.
   PubMedGoogle Scholar
• ANTMAN EM, FOR THE TIMI 9A INVESTIGATORS: Hi-rudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation (1994) 90(4):1624–1630.
   PubMed Web of Science ®Google Scholar
• WHITE HD: Clinical trials of direct thrombin inhibitors in acute ischaemic syndromes. Thromb. Haemost (1997) 78(1)364–366.
   Google Scholar
• ERICKSON BR, TOPOL EJ: Direct thrombin inhibitors in arterial thrombosis. In: New Therapeutic Agents in Thrombosis and Thrombolysis. Sasahara AA, Loscalzo J (Eds.), Marcel Dekker, Inc., New York, Basel, Hong Kong (1997) :169–189.
   Google Scholar
• GRANGER CB, VAN DE WERF F, ARMSTRONG PW et al.: Hirudin reduces death and myocardial (re)infarction at 6-months: Follow-up results of the GUSTO Ilb trial. J. Am. Coll. Cardiol (1998) 31(2, Suppl. A):79A.
   Google Scholar
• INVESTIGATORS OF THE OASIS TRIAL: Comparison of the effects of two doses of recombinant hirudin com-pared with heparin in patients with acute myocardial ischemia without ST elevation. Circulation (1997) 96(3)769–777.
   Google Scholar
• FAREED J, CALLAS D, HOPPENSTEADT DA, WALENGA JM, BICK R: Antithrombin agents as anticoagulants and an-tithrombotics. Implications in drug development. Clin. Appl. Thrombosis/Hemostasis (Submitted.)
   Google Scholar
• LIDON R, THEROUX P, JUNEAU M, ADELMAN B, MARA-GANORE J: Initial experience with a direct antithrom-bin, hirulog, in unstable angina: anticoagulant, antithrombotic, and clinical effects. Circulation (1993) 88(4R1):1495–1501.
   Google Scholar
• FUCHS J, CANNON CP, AND THE TIMI 7 INVESTIGATORS: Hirulog in the treatment of unstable angina, results of the thrombin inhibition in myocardial ischemia 7) trial. Circulation (1995) 92(4):727–733.
   PubMed Web of Science ®Google Scholar
• WHITE HD, AYLWARD PE, FREY M et al.: Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation (1997) 96 (7):2155–2161.
   PubMed Web of Science ®Google Scholar
• VERMEER F, VAHANIAN A, FELS PW et al: Intravenous ar-gatroban versus heparin as co-medication to alteplase in the treatment of acute myocardial infarction: pre-liminary results of the ARGAMI pilot study. J. Am. Coll. Cardiol (1997) 29:185–186.
   Google Scholar
• HERMANN JPR, KUTRYK JB, SERRYUS PW: Clinical trials of direct thrombin inhibitors during invasive proce-dures. Thromb. Haemost. (1997) 78(0:367–376.
   PubMedGoogle Scholar
• VAN DEN BOS AA, DECKERS JW, HEYNDRICKX GR et al.: Safety and efficacy of recombinant hirudin (CGP 39393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation (1993) 88 (5) 2058–2066.
   Google Scholar
• SERRUYS PW, HERRMAN JPR, SIMON R et al. FOR THE HELVETICA INVESTIGATORS: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. New Engl. J. Med. (1995) 333 (12):757–763.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ, BONAN R, JEWITT D et al.: Use of a direct anti-thrombin, hirulog, in place of heparin during coro-nary angioplasty. Circulation (1993) 87(5):1622–1629.
   PubMed Web of Science ®Google Scholar
• BITTL JA: Clinical trials of hirulog in patients undergo-ing high-risk percutaneous transluminal coronary an-gioplasty. Coron. Art. Dis. (1996) 7(6):449–454.
   PubMed Web of Science ®Google Scholar
• HERRMAN JPR, SURYAPRANATA H, DEN HEYER P, GAB-RIEL L, SERRUYS PW: Argatroban during percutaneous transluminal coronary angioplasty; results of a dose verification study. J. Thromb. Thrombolys. (1996) 6:367–375.
   Google Scholar
• ROWTHER MA, GINSBERG JS: Direct thrombin inhibi-tors in venous thromboembolism. In: New Therapeutic Agents in Thrombosis and Thrombolysis. Sasahara AA, Loscalzo J (Eds.), Marcel Dekker, Inc., New York, Basel, Hong Kong (1997):159–168.
   Google Scholar
• AGNELLI G, SONAGLIA F: Prevention of venous throm-boembolism in high risk patients. Haematologica (1997) 82 (4):496–502.
   PubMedGoogle Scholar
• ANDERSON DR, O'BRIEN BJ, LEVINE MN et al.: Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann. Intern. Med. (1993) 119(10:1105–1112.
   Google Scholar
• ERIKSSON BI, KALEBO P, EKMAN S et al Direct throm- bin inhibition with Rec-hirudin CGP 39393 as prophy-laxis of thromboembolic complications after total hip replacement. Thromb. Haemost (1994) 72 (2) 227–231
   PubMed Web of Science ®Google Scholar
• EKMAN S, ERIKSSON BI, LINDBRATT S et al: Recombi-nant hirudin CGP 39393 15 mg (TM Revasc-Ciba), is the most effective and safe prophylaxis of thromboem-bolic disease in patients undergoing total hip replace-ment. Thromb. Haemost. (1995) 73 (6):1093 (Abstr).
   Google Scholar
• ERIKSSON BI, EKMAN S, KALEBO P et al Prevention of deep-vein thrombosis after total hip replacement: di-rect thrombin inhibition with recombinant hirudin, CGP 39393. Lancet (1996) 347(9002):635–639.
   PubMed Web of Science ®Google Scholar
• ERIKSSON BI, WILLE-JORGENSEN P, KALEBO P et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboem-bolic complications after total hip replacement. New Engl. J. Med. (1997) 337(19):1329–1335.
   PubMed Web of Science ®Google Scholar
• GINSBERG JS, NURMOHAMED MT, GENT M et al.: Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation (1994) 90(5)2385–2389.
   Google Scholar
• BOUNAMEX H, EHRINGER H, HULTING J et al.: An ex-ploratory trial of two dosages of a novel synthetic thrombin inhibitor (Napsagatran, Ro 46-6240) com-pared with unfractionated heparin for treatment of proximal deep-vein thrombosis. Thromb. Haemost. (1997) 78:997–1002.
   PubMed Web of Science ®Google Scholar
• MOIA M, SCHIELE F, WALKER M et al: Treatment of acute deep vein thrombosis (DVT) by Sc. r-Hirudin (HEW 023): a multi-centre study. Thromb. Haemost. (1995) 73:1456.
   Google Scholar
• PARENT F, BRIDEY F, DREYFUS M eta].: Treatment of se-vere venous thrombo-embolism with iv. hirudin (HEW 023): an open-pilot study. Thromb. Haemost. (1993) 70(3):386–388.
   Google Scholar
• SCHIELE F, VUILLEMENOT A, KRAMARZ P et al.: A pilot study of sc. recombinant hirudin (HEW 023) in the treatment of deep vein thrombosis. Thromb. Haemost. (1994) 71(5):558–562.
   Google Scholar
• SCHIELE F, LINDGAERDE F, ERIKSSON H et al.: Subcuta-neous recombinant hirudin (HEW 023) versus iv. so-dium heparin in treatment of established acute deep vein thrombosis of the legs. Thromb. Haemost. (1997) 77 (5):34–838.
   Google Scholar
• RAMAKRISHNA R, MANOHARAN A, KWAN YL, KYLE PW: Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (fragmin) and heparinoid, danaparoid (orgaran). Br. J. Haematol (1995) 91(3)736–738.
   Google Scholar
• CHAMBERLIN JR, LEWIS B, LEYA F et al.: Successful treat-ment of heparin-associated thrombocytopenia and thrombosis using Hirulog. Can. J. Cardiol (1995) 11 (6):511–514.
   PubMed Web of Science ®Google Scholar
• KOZA MJ, LEWIS BE, WALENGA JM, PIFARRE R, FAREED J: Antithrombin agents in the management of heparin-induced thrombocytopenia. In: New Anticoagulants for the Cardiovascular Patient. Pifarre R (Ed.), Hanley & Belfus, Inc., Philadelphia, USA (1997):309–324.
   Google Scholar
• LEWIS BE, WALENGA JM, WALLIS DE: Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin. Thromb. Hemost. (1997) 23(2):197–202.
   PubMed Web of Science ®Google Scholar
• LEWIS BE, GRASSMANN ED, WRONA L, RANGEL Y: Novas-® tan anticoagulation during renal stent implant in a patient with heparin-induced thrombocytopenia. Blood Coag. Fibrinol (1997) 8(0:54–58.
   PubMedGoogle Scholar
• SCHIELE F, VUILLEMENOT A, KRAMARZ P et al: Use of re-combinant hirudin as antithrombotic treatment in pa-tients with heparin-induced thrombocytopenia. Am. J. Hematol (1995) 50(0:20–25.
   PubMedGoogle Scholar
• NEUHAUS KL, VAN ESSEN R, TEBBE U et al: Safety obser-vations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis study. Circulation (1994) 90(4):1638–1642.
   PubMed Web of Science ®Google Scholar
• VERSTRAETE M: Direct thrombin inhibitors: appraisal of the antithrombotic/hemorrhagic balance. Thromb. Haemost. (1997) 78(0:357–363.
   PubMedGoogle Scholar
• CALLAS D, BACHER P, IQBAL 0, HOPPENSTEADT D, FAREED J: Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin. Thromb. Res. (1994) 74(3):193–205.
   PubMed Web of Science ®Google Scholar
• CALLAS D, FAREED J: Direct inhibition of protein Ca by site directed thrombin inhibitors: implications in anti-coagulant and thrombolytic therapy. Thromb. Res. (1995) 78(5):457–460.
   PubMed Web of Science ®Google Scholar
• KAISER B, HAUPTMANN J: Factor Xa inhibitors. Facts and perspectives.
   Google Scholar
• Cardiovasc. Drug Rev. (1994) 12(3):225–236.
   Google Scholar
• KAISER B: Factor Xa vs. factor ha inhibitors. Clin. Appl. Thrombosis/Hemostasis (1997) 3 (1):16–24.
   Web of Science ®Google Scholar
• KAISER B: Thrombin and factor Xa inhibitors. Drugs Fut. (In Press.)
   Google Scholar
• HARA T, YOKOYAMA A, ISHIHARA H et al.: DX-9065a, a new synthetic, potent anticoagulant and selective in-hibitor for factor Xa. Thromb. Haemost. (1994) 71(3):314–319.
   PubMed Web of Science ®Google Scholar
• HARA T, YOKOYAMA A, TANABE K, ISHIHARA H, IWA-MOTO M: DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb. Haemost. (1995) 74 (2):635–639.
   PubMed Web of Science ®Google Scholar
• NICOLINI FA, LEE P, RIOS G, KOTTKE-MARCHANT K, TO-POL EJ: Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation (1994) 89 (4) :1802–1809.
   PubMed Web of Science ®Google Scholar
• KAWAI H, TAMAO Y: The combination of thrombin in-hibitor and thromboxane synthase inhibitor on experimental thrombosis and bleeding. Thromb. Res. (1995) 80(5):429–434.
   PubMed Web of Science ®Google Scholar
• KRUPINSKI K, BREDDIN HK: Effects of different hirud-ins and combinations of low doses of hirudin, heparin and acetylsalicylic acid in a rat microcirculatory thrombosis model. Haemostasis (1991) 21 (Suppl. 1)88–92.
   Google Scholar
• CLARKE RJ, MAYO G, FITZGERALD GA, FITZGERALD DJ: Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation (1991) 83:1510–1518.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ, BONAN R, JEWITT D eta].: Use of a direct anti-thrombin, hirulog, in place of heparin during coro-nary angioplasty. Circulation (1993) 87 (5):1622–1629.
   Google Scholar